BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26099672)

  • 1. PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
    Bouchelouche K; Choyke PL
    PET Clin; 2015 Jul; 10(3):361-74. PubMed ID: 26099672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG in Urologic Malignancies.
    Høilund-Carlsen PF; Poulsen MH; Petersen H; Hess S; Lund L
    PET Clin; 2014 Oct; 9(4):457-68, vi. PubMed ID: 26050947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Why is PET/CT essential in urooncology?].
    Borbély K; Géczi L; Kásler M
    Magy Onkol; 2013 Dec; 57(4):282-96. PubMed ID: 24353995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in urologic oncology: positron emission tomography molecular imaging.
    Bouchelouche K; Oehr P
    Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible role of FDG-PET in the evaluation of urologic malignancies.
    Bender H; Schomburg A; Albers P; Ruhlmann J; Biersack HJ
    Anticancer Res; 1997; 17(3B):1655-60. PubMed ID: 9179213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
    Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
    Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results].
    Bachor R; Kocher F; Gropengiesser F; Reske SN; Hautmann RE
    Urologe A; 1995 Mar; 34(2):138-42. PubMed ID: 7754585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposal of a new acquisition protocol for bladder cancer visualization with 18F-FDG PET/CT.
    Chondrogiannis S; Marzola MC; Colletti PM; Rubello D
    Clin Nucl Med; 2015 Jan; 40(1):e78-80. PubMed ID: 24566416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma - Today's impact, tomorrow's potential.
    Urso L; Bauckneht M; Albano D; Chondrogiannis S; Grassetto G; Lanfranchi F; Dondi F; Fornarini G; Lazzeri M; Evangelista L
    Expert Rev Med Devices; 2024; 21(1-2):55-72. PubMed ID: 38072680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
    Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiologic diagnosis and staging of renal and bladder cancer.
    Ng CS
    Semin Roentgenol; 2006 Apr; 41(2):121-38. PubMed ID: 16697891
    [No Abstract]   [Full Text] [Related]  

  • 16. A rare presentation of primary synchronous renal tract tumours on (18F)- fluorodeoxyglucose positron emission tomography- computed tomography.
    Ahmad W; Gill SM; Hassan A
    J Pak Med Assoc; 2020 May; 70(5):942-943. PubMed ID: 32400761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer.
    Yildirim-Poyraz N; Ozdemir E; Uzun B; Turkolmez S
    Rev Esp Med Nucl Imagen Mol; 2013; 32(4):214-21. PubMed ID: 23218514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does F-18 FDG-PET still play a role in metastatic renal cell carcinoma?
    Mennitto A; Grassi P; Verzoni E; Ratta R; Procopio G
    J Med Imaging Radiat Oncol; 2017 Apr; 61(2):250-251. PubMed ID: 28070961
    [No Abstract]   [Full Text] [Related]  

  • 19. [2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers].
    Bourguet P; Planchamp F; Montravers F; Vincendeau S; ;
    Prog Urol; 2007 Apr; 17(2):172-5. PubMed ID: 17489312
    [No Abstract]   [Full Text] [Related]  

  • 20. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.